Aurobindo Pharma News

Aurobindo Pharma, through its Lannett Company, has launched a generic version of Advair Diskus in the US for asthma and COPD, marking its first complex inhalati

Despite a weak market, five BSE 200 stocks, including Aurobindo Pharma, Lenskart, Coforge, Oracle Financial Services Software, and Bajaj Auto, reached new 52-we

Aurobindo Pharma's shares surged over 3% after its subsidiary, Lannett Company, launched the generic equivalent of Advair Diskus in the US, marking a significan

Indian stock market investors should monitor companies like Royal Orchid Hotels and Mahindra & Mahindra on August 31 following recent updates. Despite a positiv

Aurobindo Pharma announced that the US Food and Drug Administration (USFDA) concluded its routine inspection of its subsidiary Lannett Company LLC's facility in

Aurobindo Pharma's wholly owned US subsidiary, Lannett Company LLC, received four observations from the USFDA following a routine inspection conducted from Augu

Aurobindo Pharma's Raleigh manufacturing plant in the US has received a 'Voluntary Action Indicated' (VAI) classification from the US FDA, allowing applications

Aurobindo Pharma's subsidiary, Eugia Pharma, received a warning letter from the USFDA following an inspection of its Telangana formulation manufacturing facilit

The U.S. FDA has issued a warning letter to Eugia Pharma, a subsidiary of Aurobindo Pharma, following earlier observations and an Official Action Indicated (OAI

Aurobindo Pharma is among eight stocks from the BSE 200 index that have hit fresh 52-week highs, surging up to 20% in a month. This indicates strong investor in

Aurobindo Pharma reported a 25% increase in its Q1 net profit, reaching ₹1,032 crore, and announced the approval of a merger for three of its subsidiaries.

Aurobindo Pharma has established a new subsidiary in Indonesia focused on manufacturing operations.